Efficacy of combination chemotherapy with docetaxel and irinotecan as first- or second-line treatment for advanced gastric cancer

摘要

This study was performed to evaluate the efficacy of combination chemotherapy with docetaxel (DOC)/5-fluorouracil(5-FU)/cisplatin (CDDP) as the first-line treatment and irinotecan (CPT-11)/levofolinate/ 5-FU or CPT-11 alone as the second-line treatment for advanced gastric cancer (AGC). Seventeen patients were enrolled. The chemotherapy-induced toxicity was tolerable. The objective response rate was 11.8% (2 PR, 13 SD); the median time to progression 4.9 months; and the median overall survival time 11.2 months. The median survival time after the beginning of the second-line treatment was 6.7 months. A DOC/5-FU/CDDP combination as the first-line treatment and CPT-11-based combination as the second-line treatment seems to be effective against AGC and can improve patient survival without causing severe toxicity.